REPAIR Impact Fund makes two investments after US/Canadian investment round, totaling USD 10 million. The Fund has now invested a total of USD 30 million in six companies.
Copenhagen, Denmark, 23 July 2019 – Today, the Novo Holdings REPAIR Impact Fund announced a USD 5.25 million investment in Curza, a small-molecule therapeutics company, to accelerate its lead program, a new class of antibiotics, focused on drug-resistant Gram-negative bacteria.
“Curza is very excited to be working with Novo Holdings. Both companies have a strong commitment to bringing new antibiotics to the market to combat the growing threat of drug-resistant bacteria. Novo Holdings’ commitment to Curza allows the company to accelerate the development of a much-needed novel class of antibiotics,” said Ryan Davies, Curza’s Chief Executive Officer.
As announced previously, the REPAIR Impact Fund has also recently invested USD 5 million plus potentially additional USD 5 million in Spero Therapeutics (NASDAQ: SPRO), a clinical-stage biopharmaceutical company. Spero will use the net proceeds to advance its SPR720 program, an oral antibiotic being developed for the treatment of non-tuberculous mycobacterial (NTM) infections.